OncoMatch

OncoMatch/Clinical Trials/NCT06988059

A Study of CT0596 in Plasma Cell Leukemia

Is NCT06988059 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies CAR-T cells Infusion chimeric antigen receptor T cells for plasma cell leukemia.

Early Phase 1RecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06988059Data as of Jun 2026Location: China

Treatment: CAR-T cells Infusion chimeric antigen receptor T cellsThis study is a single-arm, open-label, exploratory dose-escalation and dosefinding clinical trial to evaluate the safety, efficacy, cellular pharmacokinetics and pharmacodynamics of CT0596 cells in patients with PCL.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

CAR-T cells Infusion chimeric antigen receptor T cells

Cancer type

Multiple Myeloma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: allogeneic stem cell transplant

Previous allogeneic stem cell transplantation

Cannot have received: autologous stem cell transplant

Exception: within 12 weeks prior to signing informed consent

autologous stem cell transplantation within 12 weeks prior to signing informed consent

Cannot have received: cell therapy

Exception: within 28 days before informed consent

Have received cell therapy within 28 days before informed consent

Cannot have received: systemic therapy for disease

Exception: within 14 days or five half-lives before preconditioning

Have received treatment for the disease within 14 days or five half-lives before preconditioning

Lab requirements

Blood counts

good organ function

Kidney function

good organ function

Liver function

good organ function

Patients should have good organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06988059 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior allogeneic stem cell transplant, autologous stem cell transplant, cell therapy disqualifies patients from enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify